Lele Song1,2, Haotian Yu1, Jia Jia1,3, Yuemin Li1. 1. The Chinese PLA 309th Hospital, Beijing 100091, China. 2. BioChain (Beijing) Science and Technology, Inc., Beijing 100176, China. 3. Graduate School of Medicine, Hebei North University, Zhangjiakou, Hebei 075000, China.
Abstract
BACKGROUND: The applications of the SEPT9 assay are expanding from CRC early diagnosis to screening, therapeutic effect monitoring and prognosis prediction. Its performance in these areas has not been thoroughly examined. OBJECTIVE: We aim to evaluate the performance of the SEPT9 assay in CRC screening, diagnosis and therapy by reviewing the current data published in these aspects. METHODS: The Ovid MEDLINE, EMBASE, CBMdisc (China Biology Medicine disc) and CJFD (Chinese Journal Full - text Database) database were searched for potential reports on the assay performance. Letters, reviews, meta-analysis and guidelines, basic research studies and articles irrelevant to mSEPT9 detection assays were excluded. Finally, data from 19 studies was summarized and systematically reviewed to clarify the assay performance. RESULTS: 2/3 algorithm provided the best overall performance in diagnosis and screening, while the 1/3 algorithm exhibited the best sensitivity in screening. The combination of SEPT9 assay with FIT and/or CEA enhanced the CRC detection rate in screening. The SEPT9 assay appeared to be effective in monitoring the therapeutic effect and may potentially predict the CRC recurrence and survival. CONCLUSION: The SEPT9 assay exhibited satisfactory performance in CRC diagnosis and screening, while more evidence is needed for therapeutic effect monitoring and prognosis prediction.
BACKGROUND: The applications of the SEPT9 assay are expanding from CRC early diagnosis to screening, therapeutic effect monitoring and prognosis prediction. Its performance in these areas has not been thoroughly examined. OBJECTIVE: We aim to evaluate the performance of the SEPT9 assay in CRC screening, diagnosis and therapy by reviewing the current data published in these aspects. METHODS: The Ovid MEDLINE, EMBASE, CBMdisc (China Biology Medicine disc) and CJFD (Chinese Journal Full - text Database) database were searched for potential reports on the assay performance. Letters, reviews, meta-analysis and guidelines, basic research studies and articles irrelevant to mSEPT9 detection assays were excluded. Finally, data from 19 studies was summarized and systematically reviewed to clarify the assay performance. RESULTS: 2/3 algorithm provided the best overall performance in diagnosis and screening, while the 1/3 algorithm exhibited the best sensitivity in screening. The combination of SEPT9 assay with FIT and/or CEA enhanced the CRC detection rate in screening. The SEPT9 assay appeared to be effective in monitoring the therapeutic effect and may potentially predict the CRC recurrence and survival. CONCLUSION: The SEPT9 assay exhibited satisfactory performance in CRC diagnosis and screening, while more evidence is needed for therapeutic effect monitoring and prognosis prediction.
Authors: Mark Lawler; Deborah Alsina; Richard A Adams; Annie S Anderson; Gina Brown; Nicola S Fearnhead; Stephen W Fenwick; Stephen P Halloran; Daniel Hochhauser; Mark A Hull; Viktor H Koelzer; Angus G K McNair; Kevin J Monahan; Inke Näthke; Christine Norton; Marco R Novelli; Robert J C Steele; Anne L Thomas; Lisa M Wilde; Richard H Wilson; Ian Tomlinson Journal: Gut Date: 2018-01 Impact factor: 23.059
Authors: Luka de Vos; Heidrun Gevensleben; Andreas Schröck; Alina Franzen; Glen Kristiansen; Friedrich Bootz; Dimo Dietrich Journal: Clin Epigenetics Date: 2017-12-01 Impact factor: 6.551
Authors: Julia Bergheim; Alexander Semaan; Heidrun Gevensleben; Susanne Groening; Andreas Knoblich; Jörn Dietrich; Julia Weber; Jörg C Kalff; Friedrich Bootz; Glen Kristiansen; Dimo Dietrich Journal: Br J Cancer Date: 2018-04-03 Impact factor: 7.640